Cortagen (AEDP) record · updated 20h ago
Cortagen (AEDP) is a synthetic tetrapeptide cortex bioregulator from the Khavinson family, researched primarily for neuroprotection, cognitive support, and recovery after brain or nerve injury.
How it works: modulates gene expression, influences neuroprotection and immune response
Development stage
where Cortagen (AEDP) sits between preclinical work and regulatory approval- 1CurrentPreclinicalAnimal / in-vitro work
- 2Not reachedPhase 1Safety in humans
- 3Not reachedPhase 2Efficacy signal
- 4Not reachedPhase 3Confirmatory trials
- 5Not reachedApprovedCleared by a regulator
Stage is inferred from the highest trial phase in the indexed corpus. It describes the research record, not a recommendation.
Mass and formula from PubChem CID 18439621. No verified residue count for this compound.
| Study | Type | Year | Summary depth |
|---|---|---|---|
| Elucidation of the effect of brain cortex tetrapeptide Cortagen on gene expression in mouse heart by microarray. FindingMaximum up-regulation of gene expression was +5.42. | Animal | 2004 | Full text read0.70 |
What people are saying
anecdotal · not evidenceUnverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Cortagen (AEDP) will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.